Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type

Blood

Volumn 102, Issue 8, 2003, Pages 2741-2745

  Conconi, Annarita ^b   Martinelli, Giovanni ^b   Thiéblemont, Catherine ^b   Ferreri, Andrés J M ^b   Devizzi, Liliana ^b   Peccatori, Fedro ^b   Ponzoni, Maurilio ^b   Pedrinis, Ennio ^b   Dell'Oro, Stefania ^b   Pruneri, Giancarlo ^b   Filipazzi, Virginio ^b   Dietrich, Pierre Yves ^b   Gianni, Alessandro M ^b   Coiffier, Bertrand ^b   Cavalli, Franco ^b   Zucca, Emanuele ^a  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANGIONEUROTIC EDEMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EXTRANODAL MARGINAL ZONE B CELL LYMPHOMA; FEMALE; FEVER; FOLLOW UP; GLOTTIS EDEMA; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; HYPOTENSION; INFECTION; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTICENTER STUDY; NONHUMAN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RASH; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH; STOMACH HEMORRHAGE; STOMACH LYMPHOMA; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR LOCALIZATION;

EID: 0141923917     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-11-3496     Document Type: Article

References (41)

1. Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood. 2000;96:410-419.
2. Cavalli F, Isaacson PG, Gascoyne RD, Zucca E. MALT Lymphomas. Hematology (Am Soc Hematol Educ Program). 2001:241-258.
3. Isaacson PG, Muller-Hermelink HK, Piris MA, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology & Genetics: tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001:157-160.
4. Zucca E, Conconi A, Pedrinis E, et al. Non-gastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101:2489-2495.
5. Hitchcock S, Ng AK, Fisher DC, et al. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2002;52:1058-1066.
6. Thieblemont C, Bastion Y, Berger F, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol. 1997;15: 1624-1630.
7. Du M-Q, Isaacson P. Gastric MALT lymphoma: from aetiology to treatment to cure. Lancet Oncol. 2002;3:97-104.
8. Bertoni F, Conconi A, Capella C, et al. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood. 2002;99:2541-2544.
9. Thiede C, Wundisch T, Alpen B, et al. Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol. 2001; 19:1600-1609.
10. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95:802-806.
11. Zinzani P, Magagnoli M, Galieni P, et al. Non-gastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol. 1999;17:1254-1258.
12. Pinotti G, Zucca E, Roggero E, et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymphoma. 1997;26:527-537.
13. Hammel P, Haioun C, Chaumette MT, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol. 1995;13:2524-2529.
14. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol. 1998;16:1916-1921.
15. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys. 2001;50:1258-1264.
16. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
17. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317-324.
18. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstroem's macroglobulinemia with rituximab. J Clin Oncol. 2002;20:2327-2333.
19. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-1932.
20. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-276.
21. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001;19:389-397.
22. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
23. Soda R, Costanzo A, Cantonetti M, et al. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody. Acta Derm Venereol. 2001;81:207-208.
24. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
25. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group [published erratum appears in J Clin Oncol. 2000; 18:2351]. J Clin Oncol. 1999;17:1244-1253.
26. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group [published erratum appears in J Clin Oncol. 2000; 18:2351]. J Clin Oncol. 1999;17:1244-1253.
27. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphomas. N Engl J Med. 1993;329:987-994.
28. Common Toxicity Criteria Manual (PDF) [updated August 18,1999], CTC v. 2.0. Reference document available at http://ctep.cancer.gov/reporting/ctc.html. Accessed August 19, 2003.
29. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer. 1995;72:511-518.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
31. Siegel S. Nonparametric Statistics. New York, NY: McGraw Hill; 1956.
32. Hainsworth JD, Litchy S, Burris HA III, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:4261-4267.
33. Cogliatti SB, Schmid U, Schumacher U, et al. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology. 1991; 101:1159-1170.
34. Streubel B, Lamprecht A, Dierlamm J, et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood. 2003;101:2335-2339.
35. Sanchez-Izquierdo D, Buchonnet G, Siebert R, et al. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood. 2003;101:4539-4546.
36. Ye H, Liu H, Attygalle A, et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of Hpyloriin gastric MALT lymphoma. Blood. 2003;102:1012-1018.
37. Liu H, Ruskone-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357:39-40.
38. Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood. 2001;97:1392-1398.
39. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a foJJicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol. 2001;114:800-809.
40. Ghielmini M, Hsu Schmitz S-F, Cogliatti S, et al. Maintenance treatment with 2-monthly rituximab after standard weekly ×4 rituximab induction significantly improves event-free survival in patients with follicular lymphoma [abstract]. Ann Oncol. 2002;13(suppl 2):38.
41. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1999;10:655-661.